NCT05799183 2024-12-31
A SHR-1210 BE Study on Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
Clinical Trials
9 trialsNCT03871855 2023-06-05
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT02721589 2023-02-28
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02742935 2023-02-27
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03182673 2022-09-01
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03121716 2022-07-12
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02492789 2019-09-30
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
Atridia Pty Ltd.
Phase 1 Completed
NCT03393416 2019-08-29
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
HRYZ Biotech Co.
Phase 1 Unknown